The xCures technology platform uses artificial intelligence (A.I.) and predictive modeling to identify and rank the most promising treatment options for advanced cancer patients who are not responding to standard of care therapies.

Patients pay with their data. They sign a HIPAA release giving xCures the right to request their medical records. The platform then provides these patients a personalized list of top treatment options and information about how to access them. 

The xCures platform captures Real World Evidence (RWE) from patients being treated in clinical trials, compassionate use and managed access programs, virtual and decentralized studies, investigator-initiated studies, and even N-of-1 clinical studies.

The RWE is used to accelerate the development of new drugs, expand the approved uses of existing drugs, and demonstrate value for reimbursement. The platform accepts records from any US-based institution, in any form, and compiles the data into a pan-cancer registry under an IRB-approved master protocol suitable for FDA submissions and medical publications.

xCures makes it possible to learn from the experiences of all patients who give us their data in return for treatment options, and optimize options selection for future patients.

The xCures technology platform uses artificial intelligence (A.I.) and predictive modeling to identify and rank the most promising treatment options for advanced cancer patients who are not responding to standard of care therapies.

Patients pay with their data. They sign a HIPAA release giving xCures the right to request their medical records. The platform then provides these patients a personalized list of top treatment options and information about how to access them. 

The xCures platform captures Real World Evidence (RWE) from patients being treated in clinical trials, compassionate use and managed access programs, virtual and decentralized studies, investigator-initiated studies, and even N-of-1 clinical studies.

The RWE is used to accelerate the development of new drugs, expand the approved uses of existing drugs, and demonstrate value for reimbursement. The platform accepts records from any US-based institution, in any form, and compiles the data into a pan-cancer registry under an IRB-approved master protocol suitable for FDA submissions and medical publications.

xCures makes it possible to learn from the experiences of all patients who give us their data in return for treatment options, and optimize options selection for future patients.

C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. The cancer intelligence company is developing a platform that can perform whole-genome sequencing using only 2 milliliters of blood. Its ultra-sensitive liquid biopsy assay allows physicians to monitor patient treatment response and detect treatment failure or disease recurrence months and potentially years earlier than current monitoring methods. C2i’s cancer diagnostics service uses artificial intelligence pattern recognition and the whole-genome analysis to spot trace amounts of cancer much quicker, in about a week, to inform better treatment decisions and ultimately save lives. The company aims to help patients avoid unnecessary overtreatment with toxic chemotherapy or radiation, as well as to prevent them from going without treatment while cancer quietly grows and metastasizes. In 2019, Boris Oklander, Asaf Zviran, and Ezra Sofer established the company in New York, New York.